BeiGene (NASDAQ:BGNE) is trading 2.4% lower

The shares of BeiGene, Ltd. (NASDAQ:BGNE ​​- Get Free Report) fell 2.4% on Friday. The stock traded as low as $126.97 and last traded at $128.77. During afternoon trading, 17,319 shares traded, down 93% from the average session volume of 256,444 shares. The stock previously closed at $131.96.

Analysts set new price targets

A number of brokers have commented on BGNE. Sanford C. Bernstein lowered their target price on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a report on Wednesday, March 27. Guggenheim lowered their price objective on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a report on Tuesday, February 27. Bank of America lowered their target price on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a report on Monday, April 8. Finally, JPMorgan Chase & Co. raised their price target for shares of BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of ‘Moderate Buy’ and a consensus price target of $251.70.

Get our latest analysis on BeiGene

BeiGene is trading 1.8% lower

The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 2.32. The company has a market cap of $12.39 billion, a price-to-earnings ratio of -15.24 and a beta of 0.61. The company’s 50-day simple moving average is $155.08 and its 200-day simple moving average is $168.23.

BeiGene (NASDAQ:BGNE ​​​​ – Get Free Report) last reported its earnings results on Monday, February 26. The company reported ($3.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The company had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. During the same period last year, the company posted earnings per share ($4.29). The company’s revenue increased by 66.9% compared to the same quarter last year. On average, research analysts expect BeiGene, Ltd. will post a profit per share of -8.87 for the current financial year.

Buying and selling with insider information at BeiGene

In related news, CFO Julia Aijun Wang sold 397 shares of stock in a transaction that occurred on Thursday, February 29th. The shares sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a filing with the SEC, which can be accessed via this link. In related news, CFO Julia Aijun Wang sold 397 shares of stock in a transaction that occurred on Thursday, February 29th. The shares sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a filing with the SEC, which can be accessed via this link. Also, CEO John Oyler sold 26,716 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the sale, the CEO now owns 12,084 shares of the company’s stock, valued at $1,799,186.76. The explanation of this sale can be found here. In the last three months, insiders have sold 64,781 shares of the company’s stock worth $10,222,381. Company insiders own 7.40% of the company’s shares.

Institutional trading in BeiGene

Hedge funds have recently changed their positions in the company. E Fund Management Hong Kong Co. Ltd. increased its stake in BeiGene by 137.7% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 27,501 shares of the company’s stock worth $5,071,000 after purchasing an additional 15,929 shares during the period. Raymond James & Associates increased its stake in BeiGene by 24.9% during the first quarter. Raymond James & Associates now owns 15,273 shares of the company’s stock worth $2,880,000 after purchasing an additional 3,047 shares during the period. Bank of New York Mellon Corp increased its stake in BeiGene by 0.6% during the first quarter. Bank of New York Mellon Corp now owns 55,199 shares of the company’s stock worth $10,409,000 after purchasing an additional 308 shares during the period. American Century Companies Inc. increased its stake in BeiGene by 7.9% during the first quarter. American Century Companies Inc. now owns 3,458 shares of the company’s stock worth $652,000 after purchasing an additional 254 shares during the period. Finally, Bank of Montreal Can increased its stake in BeiGene by 19.7% in the first quarter. Bank of Montreal Can now owns 14,571 shares of the company’s stock worth $3,001,000 after purchasing an additional 2,396 shares during the period. 48.55% of the shares are currently held by institutional investors and hedge funds.

BeiGene company profile

(Get a free report)

BeiGene, Ltd. is engaged in the development and commercialization of oncology medicines worldwide through its subsidiaries. Products include BRUKINSA for the treatment of various forms of blood cancer; TEVIMBRA for the treatment of various forms of solid tumors and blood cancers; PARTRUVIX for the treatment of various malignant tumors of solid tumors; XGEVA for the treatment of bone metastases from solid tumors and multiple myeloma, as well as from giant cell tumor of the bone; BLINCYTO for the treatment of acute lymphocytic leukemia; KYPROLIS for the treatment of R/R multiple myeloma; REVLIMID for the treatment of multiple myeloma; VIDAZA for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia; SYLVANT for the treatment of idiopathic multicentric Castleman disease; QARZIBA for the treatment of neuroblastoma; POBEVCY for the treatment of metastatic colorectal cancer, liver cancer and non-small cell lung cancer (NSCLC); BAITUOWEI, for the treatment of breast and prostate cancer; TAFINLAR and MEKINIST for the treatment of NSCLC and melanoma; VOTRIENT for advanced renal cell carcinoma; AFINITOR for advanced renal cell carcinoma, NET, SEGA and breast cancer; and ZYKADIA for the treatment of ALK + NSCLC.

Recommended articles

Receive daily news and reviews for BeiGene – Enter your email address below to receive a concise daily digest of the latest news and analyst ratings for BeiGene and related companies with MarketBeat.com’s FREE daily email newsletter.